Literature DB >> 10537961

Prescribing at the interface between primary and secondary care in the UK. Towards joint formularies?

M Duerden1, T Walley.   

Abstract

The current divisions in managing prescribing between primary and secondary care in the UK arise from separate budgetary arrangements. These divisions are neither sensible, organisationally efficient nor cost effective. Transition of patients across the interface of primary and secondary care has always been problematic, hindered by poor communication and coordination. Joint formularies would improve overall care and raise awareness of the need to consider overall costs within a unified National Health Service (NHS). There are, however, few examples of successful working of a joint formulary in the UK. It is likely that harmonisation of drug use in hospitals and in primary care will come about because of contracting and commissioning, and that it will largely be led by primary care, through the developing primary care groups (PCGs). Local decisions around availability and use of drug therapies will increasingly be superseded by the national decisions emanating from the newly formed National Institute for Clinical Effectiveness.

Entities:  

Mesh:

Year:  1999        PMID: 10537961     DOI: 10.2165/00019053-199915050-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  30 in total

1.  A UK national prescribing list?

Authors:  T Walley
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

2.  Viagra is licensed in Europe, but rationed in Britain.

Authors:  A Brooks
Journal:  BMJ       Date:  1998-09-19

3.  Testing of PRODIGY continues.

Authors:  I Purves; G Nestor; K Williams
Journal:  BMJ       Date:  1998-03-07

4.  Sharing resources to create a district drug formulary: a countywide controlled trial.

Authors:  I Hill-Smith
Journal:  Br J Gen Pract       Date:  1996-05       Impact factor: 5.386

5.  Adherence to the Grampian joint drug formulary in general practice.

Authors:  D Stewart; K Milne; J Krska; G Downie
Journal:  J Clin Pharm Ther       Date:  1996-04       Impact factor: 2.512

6.  A stakeholder analysis of developments at the primary and secondary care interface.

Authors:  D Evans
Journal:  Br J Gen Pract       Date:  1996-11       Impact factor: 5.386

7.  Introduction and audit of a general practice antibiotic formulary.

Authors:  A Needham; M Brown; S Freeborn
Journal:  J R Coll Gen Pract       Date:  1988-04

8.  Transferring the costs of expensive treatments. Guidelines may clarify responsibility for prescribing.

Authors:  M Young; S Colwill; J Spiby
Journal:  BMJ       Date:  1995-05-20

9.  The selected list.

Authors:  D N Bateman
Journal:  BMJ       Date:  1993-05-01

10.  Prescribing at the hospital-general practice interface. I: Hospital outpatient dispensing policies in England.

Authors:  P Wilkie; B Sibbald; J Raftery; S Anderson; P Freeling
Journal:  BMJ       Date:  1992-01-04
View more
  5 in total

1.  Insufficient communication about medication use at the interface between hospital and primary care.

Authors:  Bente Glintborg; Stig Ejdrup Andersen; Kim Dalhoff
Journal:  Qual Saf Health Care       Date:  2007-02

2.  Congruence on medication between patients and physicians involved in patient course.

Authors:  S Foss; J R Schmidt; T Andersen; J J Rasmussen; J Damsgaard; K Schaefer; L K Munck
Journal:  Eur J Clin Pharmacol       Date:  2003-12-19       Impact factor: 2.953

3.  Evaluation of angiotensin II receptor blockers for drug formulary using objective scoring analytical tool.

Authors:  Tsuey M Lim; Mohamed I Ibrahim
Journal:  Pharm Pract (Granada)       Date:  2012-09-30

4.  Biosimilar uptake by British local formularies: a cross sectional study.

Authors:  Saja Alnahar; Rachel A Elliott; Murray D Smith
Journal:  Int J Clin Pharm       Date:  2017-09-04

5.  The influence of hospitalisation on drug prescription in primary care--a large-scale follow-up study.

Authors:  Thomas Grimmsmann; Ulrike Schwabe; Wolfgang Himmel
Journal:  Eur J Clin Pharmacol       Date:  2007-06-05       Impact factor: 3.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.